clinical trial · NCT04204616
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
Galderma R&D·phase3·active not recruiting·n = 500
Prurigo NodularisNemolizumab
brief summary
The primary purpose of this study is to assess the long-term safety of nemolizumab (CD14152) in participants with prurigo nodularis (PN).
started
Jan 11, 2021
primary completion
Oct 26, 2026
completion
Oct 26, 2026
last updated
Nov 12, 2025
official title
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol